Frequently Asked Questions about Cancer Associated Thrombosis
|
|
- Sybil Sherman
- 6 years ago
- Views:
Transcription
1 + Frequently Asked Questions about Cancer Associated Thrombosis Atlantic Canada Oncology Group Annual Meeting June 13 th, 2015 Sudeep Shivakumar, Dalhousie University
2 + Conflict of Interest Disclosures Pharmaceutical Company Affiliations" None" Grants/Research Support" None" Speakers Bureau/Advisory Boards" Boehringer-Ingelheim" Bayer Inc" Leo Pharma" Consulting Fees" None
3 + Objectives! To discuss the link between cancer and thrombosis! To highlight the specific difficulties in patients with malignancies! To present an approach to management of patients with thrombosis in malignancy:! Catheter associated thrombosis! Recurrent thrombosis! Thrombocytopenia! Incidentally discovered pulmonary embolism
4 + Background! Venous thromboembolism (VTE)! Deep venous thrombosis (DVT) and pulmonary embolism (PE)
5 + Cancer and thrombosis " Patients with cancer more prone to venous thromboembolism (VTE) " Population study of 625 Minnesota patients showed: " Patients with cancer 4.5x more likely to have VTE " Patients with cancer receiving chemotherapy 6.5x more likely to have VTE " Estimated risk: 1 in 200 Heit, Arch Int Med, 2000
6 + Cancer and thrombosis " Why do patients with cancer get blood clots? " Immobility " Central venous catheters " Post-surgery " Medications (tamoxifen, thalidomide) " Chemotherapy " Tumour infiltration into vessels " Vessel obstruction
7 + Cancer and thrombosis " Are some cancers more prone to VTE? " Swedish autopsy study looking at patients with DVT or PE " Highest risk in uterine, brain, ovarian cancer and leukemia " However, data varies between studies " Metastatic adenocarcinoma generally felt to be very thrombogenic Thodiyil, Thromb Haemost, 2002
8 + Prognosis of VTE in cancer " Data from national registry of patients in Denmark further analyzed " Compared outcomes of patients with cancer and DVT or PE with patients with cancer without DVT or PE " Concluded that patients with DVT or PE did worse Sorensen, NEJM, 2000
9 + Prognosis of VTE in cancer " Patients with VTE had more distant metastases (44% vs 35%) " Prognosis poorer as well: " Those with VTE at time of diagnosis of cancer had 1 year survival of 12% (vs. 36% in those who did not have VTE) Sorensen, NEJM, 2000
10 + Prognosis of VTE in cancer! More recent data:! Prospective observational study of cancer patients starting new chemo regimen in US! 4466 patients enrolled! 141 died during observation period (4 cycles of chemo)! Thromboembolism (arterial and venous) = cause of death in 9.2% (tied for 2 nd with infection) Cause of death n (%) Progression of cancer 100 (70.9) Thromboembolism 13 (9.2) Infection 13 (9.2) Respiratory failure 5 (3.5) Bleeding 2 (1.4) Aspiration pneumonia 2 (1.4) Other 9 (6.4) Unknown 5 (3.5) Khorana, JTH, 2007
11 + Treatment of VTE! Typically, long term therapy for VTE is with vitamin K antagonists (VKA)! Treat with low molecular weight heparin for at least 5 days! Overlap with warfarin! Once INR is between 2 and 3, stop LMWH! Continue warfarin for 3-12 months (or longer)
12 + Treatment of VTE! Difficulties with VKA in patients with cancer:! Unpredictable anticoagulant response! Drug interactions! Changes in vitamin K status! Liver dysfunction! GI disturbances such as vomiting and diarrhea! Need for venipuncture (painful, time consuming)! Difficult to manage b/c of slow onset/offset for procedures, ORs, thrombocytopenia Lee, Best Pract Res Clin Hem, 2009
13 + Treatment of VTE! Low molecular weight heparin! No laboratory monitoring! Minimal drug interactions! Subcut administration ensures drug delivery in those who can t eat or have N/V! Easy to withhold for procedures, low platelets, etc! Several trials have compared LMWH to VKAs in patients with cancer
14 + CLOT trial! 2003 international randomized trial of 672 patients! All had cancer and symptomatic VTE! All initially received dalteparin for 5-7 days! Randomized to:! Continue dalteparin for total of 6 months! Full dose x 1 month, then 75-80% dose x 5 months, or! Switch to warfarin for 6 months Lee, NEJM, 2003
15 + CLOT trial! Results! Reduced relative risk of recurrent VTE in dalteparin group by 52%! 9% in dalteparin group, 17% in warfarin group! No significant differences in bleeding or survival! NNT of 13 Lee, NEJM, 2003 Figure 1. Kaplan Meier Estimates of the Probability of Symptomatic Recurrent Venous Thromboembolism among Patients with Cancer, According to Whether They Received Secondary Prophylaxis with Dalteparin or Oral Anticoagulant Therapy for Acute Venous Thromboembolism.
16 + Challenges in cancer associated thrombosis! Catheter associated thrombosis! Recurrent thrombosis while on anticoagulation! Thrombocytopenia! Incidental pulmonary embolism
17 + Challenges in cancer associated thrombosis! Catheter associated thrombosis! Recurrent thrombosis while on anticoagulation! Thrombocytopenia! Incidental pulmonary embolism
18 + Case: Mr. RB! 68 year old gentleman with newly diagnosed diffuse large B- cell lymphoma, stage 3B! Previously well except for HTN! No history of DVT/PE! Undergoes 2 cycles of R-CHOP chemotherapy, no complications! Very difficult venous access so PICC placed in left arm for further cycles
19 + Case: Mr. RB! After 2 further cycles R-CHOP, left arm swollen (wedding band doesn t fit) and painful! Exam shows:! HR 80, BP 162/95, O2 sat 99% on room air, afebrile.! Clear chest, normal heart sounds, benign abdomen.! Left arm swollen, red, warm and tender.! Dilated chest wall veins noted! PICC site clean, not red.! Sent for ultrasound:! Confirms presence of left subclavian vein thrombosis
20 + Case: Mr. RB! Does this need treatment?
21 +! Veins of the upper extremity Gray s Anatomy
22 +! Veins of the upper extremity Gray s Anatomy
23 + Case: Mr. RB! How would you anticoagulate him?
24 + Case: Mr. RB! Treatment: 1. Low molecular weight heparin (LMWH) overlapped with warfarin 2. Low molecular weight heparin alone 3. Direct oral anticoagulants
25 + Case: Mr. RB! Treatment:! Low molecular weight heparin (LMWH) overlapped with warfarin! Standard treatment for DVT/PE! Low molecular weight heparin alone! CLOT trial! Direct oral anticoagulants! Ongoing studies
26 + Treatment! Should the PICC line be removed?! PICC is provoking factor for clot! However, many patients will still require catheter access! Insertion of another line may further increase the thrombotic risk! Is line salvage an option?
27 + Treatment! Catheter study! Prospective cohort study of 74 patients! All had symptomatic UE DVT and cancer! All treated with dalteparin overlapped with warfarin! Treated for minimum 3 months! Catheter not removed Kovacs et al, J Thromb Haemost, 2007
28 + Treatment! Catheter study! Results:! Majority had PICC lines (77%)! 42 (57%) had catheter in place and functional at 3 months! At 3 months:! 3 episodes of major hemorrhage! No patients with recurrent VTE! 7 deaths: 1 due to hemorrhage, 6 due to malignancy Kovacs et al, J Thromb Haemost, 2007
29 + Treatment! Suggests that decision to remove catheter after a thrombotic event should be balanced with other factors:! Need for venous access! Difficulty of venous access! Patient preference! ACCP guidelines consistent with this:! Do not recommend removal of an indwelling catheter if the device is functioning and there is an ongoing need for the catheter (grade 2C) ACCP Guidelines, Chest, 2012
30 + Treatment! How long do you anticoagulate for?
31 + Treatment! Duration of treatment also controversial! Wide range of treatment durations reported, from weeks to months! ACCP guidelines recommend treatment duration consistent with LE DVT! In those who have a catheter removed, duration should not be shortened to less than 3 months (grade 2C)! Extrapolations:! Treat with anticoagulation for 3 to 6 months, with consideration of LMWH for patients with cancer! Continue anticoagulation as long as catheter is in place?! Indefinite anticoagulation if recurrent VTE ACCP Guidelines, Chest, 2012
32 + Case: Mr. RB! Starts on LMWH monotherapy and catheter left in! After 3 months, arm is back to normal, chemo is finished and catheter is removed! Follow up PET shows complete metabolic response! LMWH is stopped
33 + Challenges in cancer associated thrombosis! Catheter associated thrombosis! Recurrent thrombosis while on anticoagulation! Thrombocytopenia! Incidental pulmonary embolism
34 + Case: Ms. GD! 56 year old female with stage III ovarian cancer with residual disease! Undergoing chemotherapy with Carbo/Taxol! After one cycle, develops right leg swelling and pain! U/S confirms right leg DVT! Treated as per CLOT trial with LMWH monotherapy
35 + Case: Ms. GD! Continues on LMWH but after further chemotherapy cycles develops shortness of breath and pleuritic chest pain! CT-PE shows bilateral pulmonary emboli! What do we do now?
36 + Management considerations! Confirm that there is no tumour or disease progression! Confirm compliance with anticoagulation! Any weight change?! Any new risk factors?! Any evidence of heparin induced thrombocytopenia (HIT)?
37 + Recurrent VTE! Note that 9-17% of patients with cancer in CLOT developed recurrent VTE over 6 months, while on therapy with LMWH or VKA! Overall survival of these patients poor! 60% mortality within 1 year of VTE diagnosis! What treatment options are there?! Little published data
38 + Recurrent VTE! Previous CHEST guidelines recommended IVC filters in patients with recurrent VTE while on anticoagulants! Randomized trials have shown decreased PE, but increased DVT! However, risk of recurrent DVT with IVCF as high as 32% in patients with cancer (Elting, Arch Int Med, 2004)! Not recommended in latest (2012) guidelines
39 + Recurrent VTE! Increase the dose of LMWH?! Looked at in retrospective cohort study! Patients on VKA switched to LMWH therapeutic dose! Patients on LMWH were dose escalated! If on 75% dose, increased to 100% dose x 6-12 weeks! If on 100% dose, increased to % dose x 4 weeks! If on low dose, increased to 100% dose x 4 weeks, then 75%! Followed for 3 months Carrier, JTH, 2009
40 + Recurrent VTE! Results:! 70 patients with cancer and a recurrent VTE, despite anticoagulation! 6 patients (8.6%) had a second recurrent VTE during 3/12 follow up! All had doses further increased by 20-25%! No further events during 3/12 follow up (ie. no third VTE!)! 4.3% of patients had bleeding complications! Two minor events, and one intracranial bleed assoc. with brain tumour! Suggests increasing LMWH is a reasonable option, with acceptable rates of bleeding Carrier, JTH, 2009
41 + Case: Ms. GD! Treated with split dose LMWH! Dalteparin 120 units/kg BID! No further thrombosis!
42 + Challenges in cancer associated thrombosis! Catheter associated thrombosis! Recurrent thrombosis while on anticoagulation! Thrombocytopenia! Incidental pulmonary embolism
43 Case: Ms. MT! 68yo with relapsed lymphoma! Left leg swelling in your office.! Doppler: Occlusive thrombus in the left superficial femoral vein.! egfr: 60 cc/min, Hb: 115 g/l and plt: 200 X 10 9 /L! Started on therapeutic doses of LMWH
44 + Case: Ms. MT! Received R-GDP chemotherapy for salvage therapy before autostem cell transplant! Seen in your clinic for two-week follow-up! Symptoms are improving! No signs or symptoms of recurrent VTE! Repeated blood work showed:! egfr: 55 cc/min, Hb 90 g/l, WBC 1.0 (neutro 0,3), and plt: 55 X 10 9 /L.! How would you manage Ms. MT?
45 + What would you do? A. Stop LMWH B. Stop LMWH and insert IVC filter C. Continue same dose of LMWH and repeat blood work in one week D. Decrease LMWH to 50% therapeutic doses E. Decrease LMWH to thromboprophylactic doses
46 + Important factors to consider 1. Etiology of the thrombocytopenia! e.g. HIT, chemotherapy effect, etc 2. Severity ( or < 50 X 10 9 /L) 3. Expected duration and course! transient or permanent! nadir or will drop further 4. Reversible causes that can be corrected 5. Other risk factors for bleeding! e.g. Advanced age or recent surgery.
47 + Management! For acute VTE (< 30 days) Carrier M et al. J Thromb Haemost Jun 27. Lee AY et al Blood 2013; epub ahead of print. Monreal M. J Thromb Haemost 2004 Aug;2(8): Lee AYY et al. N Engl J Med :
48 Management! For sub-acute VTE (> 30 days) Carrier M et al. J Thromb Haemost Jun 27. Lee AY et al Blood 2013; epub ahead of print. Monreal M. J Thromb Haemost 2004 Aug;2(8): Lee AYY et al. N Engl J Med :
49 + Challenges in cancer associated thrombosis! Catheter associated thrombosis! Recurrent thrombosis while on anticoagulation! Thrombocytopenia! Incidental pulmonary embolism
50 Case: Mr. MC! 25yo male with testicular cancer! Routine computed tomography (CT) of the chest for cancer staging.! Called by the radiologist because bilateral segmental and subsegmental PE incidentally found on CT.! Patients denies chest pain, shortness of breath or hemoptysis.! How will you manage Mr. MC?
51 What will you do? A. Observation only (+/- repeating imaging) B. LMWH in combination with VKA for minimum of 6 months C. LMWH only (+/- dose reduction) for minimum of 6 months D. Rivaroxaban 15 mg BID X 3 weeks then 20 mg daily for minimum of 6 months
52 Risk of incidental PE in cancer patients! Approx 1 to 4% of routine CT Chest staging! In-patients > outpatients! Risk factors:! Metastatic disease! Recent chemotherapy! Types of cancer:! Pancreas! Melanoma/skin! Hepatobiliary! Kidney Browne AM et al. J Thorac Oncol. 2010;5: Douma RA et al. Thromb Res 2010; 25:e306-e309. Shinagore AB et al. Cancer. 2011; 117:
53 Cumulative risk of recurrent VTE Incidental Vs. Symptomatic PE (all receiving anticoagulation) Incidental PE: n=51 Symptomatic PE: n=144 Figure from: den Exter P L et al. JCO 2011;29:
54 Cumulative Survival Rates Incidental Vs. Symptomatic PE Figure from: den Exter P L et al. JCO 2011;29:
55 Overall survival Treated Vs. untreated incidental PE Figure from: Sun J-M et al. Lung Cancer. 2010;69:
56 Bottom Line! Patients with treated incidental PE seems to have similar rates of recurrent VTE and mortality than symptomatic events! Untreated incidental PE seems to be associated with lower survival compared to treated incidental events! Incidental PE probably benefit from anticoagulation treatment
57 + Thank you!!
Venous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationCancer Associated Thrombosis
Cancer Associated Thrombosis Can we use DOACs? D R. C Y N T H I A W U MD F R C P ( C ) D I V I S I O N O F H E M A T O L O G Y F A M I L Y P H Y S I C I A N S A N D C A N C E R C O N T R O L A P R I L
More informationCancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
More informationAnticoagulation Forum: Management of Tiny Clots
Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationManagement of Cancer Associated Thrombosis (CAT) where data is lacking. Tim Nokes Haematologist, Derriford Hospital, Plymouth
Management of Cancer Associated Thrombosis (CAT) where data is lacking Tim Nokes Haematologist, Derriford Hospital, Plymouth Contents Overview of the statistics and aetiology for Cancer Associated Thrombosis
More informationManagement of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationProphylaxie primaire sur le patient ambulatoire. Marc Carrier
Prophylaxie primaire sur le patient ambulatoire Marc Carrier Marc Carrier In compliance with COI policy, SSVQ requires the following disclosures to the session audience: Research Support/P.I. Employee
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationIs There a Role for Prophylaxis in Cancer Patients During Therapy?
Victor F. Tapson, MD, FCCP, FRCP Professor of Medicine Director, Center for Pulmonary Vascular Disease Division of Pulmonary and Critical Care Duke University Medical Center Durham, N.C. USA Is There a
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationBlood Day for Primary Care
Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,
More informationVTE General Background
VTE General Background VTE incidence is about 1:1000 persons annually >250,000 admissions for VTE annually >100,000 people die of PE annually >90% of PE s arise from lower limb DVT 50% of DVT at diagnosis
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More informationCancer Associated Thrombosis Review and Update. Family Practice Oncology CME Day November 21 st 2015 Erica Peterson
Cancer Associated Thrombosis Review and Update Family Practice Oncology CME Day November 21 st 2015 Erica Peterson Disclosures No conflicts of interest to declare Objectives To review evidence in cancer-associated
More informationNew oral anticoagulants and Palliative Care.
New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationincidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the
More informationIn the Clinic: Annals Sweta Kakaraparthi 1/23/15
In the Clinic: Annals Sweta Kakaraparthi 1/23/15 Case Scenerio 56 year old female with breast cancer presents to the clinic for her 3 month followup! She is concerned about blood clots and asks you about
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationWhat s New in DVT & PE
What s New in DVT & PE Mark Buch MD CM CCFP(EM) Attending physician Emergency Department Jewish General Hospital Family Physician and Medical Director GMF Santé Mont-Royal Objectives: Review the diagnostic
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationVenous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Nursing A guide for patients and carers Contents Why do blood clots form in veins?... 1 How common is a deep vein thrombosis (DVT) or pulmonary embolus (PE)?... 2 How are DVTs/
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationCancer associated thrombosis. 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK
Cancer associated thrombosis 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK Today What is VTE? How does CAT differ? Initial anticoagulation Anticoagulation
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationPE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP
PE and DVT Dr Anzo William Adiga WatsApp or Call +256777363201 Medical Officer/RHEMA MEDICAL GROUP OBJECTIVES DEFINE DVT AND P.E PATHOPHYSIOLOGY OF DVT CLINICAL PRESENTATION OF DVT/PE INVESTIGATE DVT MANAGEMENT
More informationCancer and Venous Thromboembolism
125 34 Cancer and Venous Thromboembolism Stephan Moll, MD University of North Carolina Chapel Hill, NC GASCO, Atlanta Sept 8 th, 2017 Disclosures Consultant: Speaker bureau: none Janssen, Boehringer-Ingelheim,
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationUpdate on the Management of Cancer Associated VTE
Update on the Management of Cancer Associated VTE Jean M. Connors, MD 2018 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Associate Professor
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationPatients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
More informationPulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical
Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationDVT and Pulmonary Embolus. Dr Piers Blombery BSc(Biomed), MBBS (Hons), FRACP, FRCPA Consultant Haematologist Peter MacCallum Cancer Centre
DVT and Pulmonary Embolus Dr Piers Blombery BSc(Biomed), MBBS (Hons), FRACP, FRCPA Consultant Haematologist Peter MacCallum Cancer Centre Overview Structure of deep and superficial venous system of upper
More informationCancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
More informationEpidermiology Early pulmonary embolism
Epidermiology Early pulmonary embolism Sitang Nirattisaikul Faculty of Medicine, Prince of Songkla University 3 rd most common cause of cardiovascular death in the United States, following ischemic heart
More informationCancer associated thrombosis
Cancer associated thrombosis Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University Take home messages 1. Clots are cool
More information2/28/16. Cancer and Venous Thromboembolism. Outline. 1. Pathophysiology and Clinical Relevance. No Disclosures
Cancer and Venous Thromboembolism No Disclosures Bob Richard, MD PhD VA Puget Sound Assoc Prof UW School of Medicine Outline 1. Pathophysiology and Clinical Relevance 2. Screening For Occult Malignancy
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationImplications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Catheter-based thrombolysis Local administration of lytic agent Higher local
More informationCancer Associated Thrombosis Approach to VTE recurrence
Cancer Associated Thrombosis Approach to VTE recurrence http://anticoag-pass-s2d.fr/ Isabelle Mahé Hôpital Louis Mourier Service de Médecine Interne APHP-Université Paris 7 EA REMES 7334-UMR 1140 France
More informationDOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
More informationThe latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationSingle Center 4 year series of 114 consecutive patients treated for massive and submassive PE. Mark Goodwin, MD
Single Center 4 year series of 114 consecutive patients treated for massive and submassive PE Mark Goodwin, MD Disclosure Speaker name:... I have the following potential conflicts of interest to report:
More informationDiagnosis of Venous Thromboembolism
Diagnosis of Venous Thromboembolism An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric Tseng MD MScCH, University of
More informationTreatment of Pediatric Venous Thromboembolism
Treatment of Pediatric Venous Thromboembolism An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric Tseng MD, MScCH, University
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationInferior Vena Cava Filter for DVT
Inferior Vena Cava Filter for DVT Deep Vein Thrombosis A deep vein thrombosis (DVT) is a blood clot that forms in a deep vein. This is a serious condition that occurs more often than you might think. If
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationInferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
More informationMy Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research
More informationROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS
ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS Chee Yen Lin Consultant Haematologist NCIS Haematology National University Hospital Singapore Nomenclature direct oral anticoagulant
More informationCanadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationPULMONARY EMBOLISM/VTE CARE PROCESS MODEL
PULMONARY EMBOLISM/VTE CARE PROCESS MODEL IMCP FALL CONFERENCE 2017 Scott Stevens, MD Co-Director, Thrombosis Clinic & Thrombosis Research Group Intermountain Medical Center Professor of Clinical Medicine
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationControversies in Venous Thromboembolism
Controversies in Venous Thromboembolism Menaka Pai, BSc MSc MD FRCPC Assistant Professor, Department of Medicine, McMaster University Associate Member, Department of Pathology and Molecular Medicine, McMaster
More informationVenous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationTreatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin
Treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin You have been given this leaflet because you have a blood clot. Normally blood flows freely around the body without
More informationDeep Vein Thrombosis and Pulmonary Embolism: Patient Information
Deep Vein Thrombosis and Pulmonary Embolism: Patient Information A Deep Vein Thrombosis (DVT) and a Pulmonary Embolism (PE) are both disorders of unwanted blood clotting. Unwanted blood clots can occur
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationUse of EKOS Catheter in the management of Venous Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group
Use of EKOS Catheter in the management of Venous Thromboembolism @ Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group Introduction Georgia Thrombosis Forum (GTF, www.gtfonline.net)
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationPulmonary Thromboembolism
Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU
More information